The -$2.40 Earnings Per Share Expected for Orexigen Therapeutics, Inc. (OREX) This Quarter

The -$2.40 Earnings Per Share Expected for Orexigen Therapeutics, Inc. (OREX) This Quarter

According to Zacks, analysts expect that Orexigen Therapeutics will report full-year earnings of ($11.47) per share for the current financial year. For the next fiscal year, analysts anticipate that the company will post earnings of ($7.04) per share. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Orexigen Therapeutics.

Equities analysts predict that Orexigen Therapeutics, Inc. (NASDAQ:OREX) will report earnings per share of ($2.40) for the current quarter, according to Zacks. Zero analysts have made estimates for Orexigen Therapeutics’ earnings. Orexigen Therapeutics posted earnings of ($1.73) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 38.7%. The business is expected to issue its next earnings results on Thursday, August 3rd.

Orexigen Therapeutics (NASDAQ:OREX) last announced its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($4.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.60) by $2.07. The firm had revenue of $19.10 million during the quarter, compared to the consensus estimate of $20 million. Orexigen Therapeutics had a negative net margin of 71.59% and a negative return on equity of 354.92%. The business’s revenue was up 282.0% compared to the same quarter last year. During the same period last year, the business earned ($1.54) earnings per share. Separately, Zacks Investment Research lowered shares of Orexigen Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, January 17th.

Orexigen Therapeutics (NASDAQ:OREX) last announced its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($4.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.60) by $2.07. The firm had revenue of $19.10 million during the quarter, compared to the consensus estimate of $20 million. Orexigen Therapeutics had a negative net margin of 71.59% and a negative return on equity of 354.92%. The business’s revenue was up 282.0% compared to the same quarter last year. During the same period last year, the business earned ($1.54) earnings per share. Shares of Orexigen Therapeutics (NASDAQ:OREX) traded down 4.6348% on Tuesday, reaching $3.2901. 206,690 shares of the company were exchanged. The firm has a 50 day moving average price of $3.16 and a 200-day moving average price of $3.13. Orexigen Therapeutics has a 12-month low of $1.65 and a 12-month high of $6.49. The stock’s market capitalization is $50.10 million.

Several institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its position in shares of Orexigen Therapeutics by 88.2% in the first quarter. Vanguard Group Inc. now owns 562,331 shares of the biopharmaceutical company’s stock worth $1,934,000 after buying an additional 263,474 shares during the last quarter. Old West Investment Management LLC bought a new position in shares of Orexigen Therapeutics during the fourth quarter worth approximately $358,000. Foresite Capital Management III LLC raised its position in shares of Orexigen Therapeutics by 49.7% in the first quarter. Foresite Capital Management III LLC now owns 380,530 shares of the biopharmaceutical company’s stock worth $1,309,000 after buying an additional 126,273 shares during the last quarter. EcoR1 Capital LLC bought a new position in shares of Orexigen Therapeutics during the first quarter worth approximately $405,000. Finally, Foresite Capital Management II LLC raised its position in shares of Orexigen Therapeutics by 14.6% in the first quarter. Foresite Capital Management II LLC now owns 622,013 shares of the biopharmaceutical company’s stock worth $2,140,000 after buying an additional 79,258 shares during the last quarter. 49.65% of the stock is currently owned by hedge funds and other institutional investors. About Orexigen Therapeutics

Orexigen Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company’s product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition.

Get a free copy of the Zacks research report on Orexigen Therapeutics (OREX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com Receive News & Ratings for Orexigen Therapeutics Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Orexigen Therapeutics Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Related posts

Leave a Comment